Related Experiment Video
Updated: Aug 11, 2025

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
Development and validation of a risk prediction model for medication administration errors among neonates in the
Josephine Henry Basil1, Chandini Menon Premakumar1, Adliah Mhd Ali1
1Centre for Quality Management of Medicines, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
Insights
Medication administration errors (MAEs) are common in neonates. This study develops a predictive risk score to identify high-risk neonates, aiming to reduce harm and healthcare costs.
Area of Science:
- Neonatal intensive care
- Patient safety
- Medication administration
Background:
- Medication administration errors (MAEs) are frequent, particularly in neonates.
- MAEs lead to severe patient harm and significant economic burden.
- No current predictive tool exists to identify neonates at high risk for MAEs.
Purpose of the Study:
- To develop and validate a risk prediction model.
- To identify neonates at high risk of medication administration errors.
- To aid in targeted interventions for reducing MAEs in neonates.
Main Methods:
- Prospective direct observational study in five neonatal intensive care units.
- Observation of at least 820 drug preparations and administrations.
- Independent error identification by two clinical pharmacists with consensus for disagreements.
Main Results:
- The study aims to develop a validated risk prediction model.
- The model will identify neonates at high risk for MAEs.
- Performance assessment of the developed model is planned.
Conclusions:
- A novel risk prediction model for neonatal MAEs is being developed.
- This tool can help prioritize high-risk neonates for targeted interventions.
- The goal is to reduce MAEs, patient harm, and healthcare costs.
Introduction:
Medication administration errors (MAEs) are the most common type of medication error. Furthermore, they are more common among neonates as compared with adults. MAEs can result in severe patient harm, subsequently causing a significant economic burden to the healthcare system. Targeting and prioritising neonates at high risk of MAEs is crucial in reducing MAEs. To the best of our knowledge, there is no predictive risk score available for the identification of neonates at risk of MAEs. Therefore, this study aims to develop and validate a risk prediction model to identify neonates at risk of MAEs.
Methods And Analysis:
This is a prospective direct observational study that will be conducted in five neonatal intensive care units. A minimum sample size of 820 drug preparations and administrations will be observed. Data including patient characteristics, drug preparation-related and administration-related information and other procedures will be recorded. After each round of observation, the observers will compare his/her observations with the prescriber's medication order, hospital policies and manufacturer's recommendations to determine whether MAE has occurred. To ensure reliability, the error identification will be independently performed by two clinical pharmacists after the completion of data collection for all study sites. Any disagreements will be discussed with the research team for consensus. To reduce overfitting and improve the quality of risk predictions, we have prespecified a priori the analytical plan, that is, prespecifying the candidate predictor variables, handling missing data and validation of the developed model. The model's performance will also be assessed. Finally, various modes of presentation formats such as a simplified scoring tool or web-based electronic risk calculators will be considered.
Related Concept Videos
Data Validation
Nursing assessment guides are generally based on holistic models rather than medical...
Factors Affecting Drug Response: Overview

